Estrella Immunopharma, Inc. Common Stock (ESLA) Stock Price
ESLAStock
$0.73−24.22%52W
Market Cap$31.86M
P/E—
PEG Ratio—
Div yield—
Beta0.91
ESLA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-52.45%
Price vs S&P 500 (4W)-4.86%
VGM Score25.83
ESLA Earnings Surprise History
Q2 25-0.15est. -0.12
Q3 25-0.13est. -0.07
Q4 25-0.01est. -0.07
Q1 26-0.05est. —
Q2 26-0.05est. -0.09
ESLA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ESLAEstrella Immunopharma, Inc. Common Stock | — | — | D | $0.73 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About Estrella Immunopharma, Inc. Common Stock
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing ARTEMIS T-cell therapies targeting CD19 and CD22 antigens for blood cancers and solid tumors. The company's engineered cell therapy approach addresses current treatment limitations in oncology and autoimmune diseases.